Climb Bio, Inc. (CLYM) News
Follow Climb Bio, Inc. (CLYM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Climb Bio Reports Phase 2 Budoprutug Data, With 70% PLA2R Reduction
Climb Bio reported initial Phase 2 data showing budoprutug reduced PLA2R antibodies by a mean 70% at Week 12 in primary membranous nephropathy.
EQUITY | Oct 26, 2026, 10:33 AM UTC
L
CLYM: Advancing two antibody assets in renal and autoimmune diseases with pivotal trials and robust data flow
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials
EQUITY | Sep 09, 2026, 10:55 PM UTC
L
CLYM: Advancing two antibody assets in renal and autoimmune diseases, with pivotal trials ahead
Two antibody programs are advancing in immune-mediated diseases, with CLYM-116 showing best-in-class potential in IgAN and budoprutug demonstrating strong efficacy in PMN and ITP. Multiple pivotal trials and data readout
EQUITY | Sep 09, 2026, 09:30 PM UTC
L
Oppenheimer maintains Outperform on Climb Bio; PT raised to $25
Oppenheimer maintained its Outperform rating on Climb Bio and raised its price target to $25.00 per share from $18.00, per Benzinga.
EQUITY | Sep 08, 2026, 05:05 PM UTC
L
Climb Bio PT raised to $32 from $20 by BTIG
BTIG raised its price target for Climb Bio to $32.00 per share from $20.00, while maintaining a Buy rating.
EQUITY | Sep 03, 2026, 06:24 PM UTC
L
CLYM PT raised by Baird; maintained Outperform
Baird maintained an Outperform rating on Clym Bio and raised its price target to $25.00 per share from $21.00, per TradingView News/Benzinga.
EQUITY | Sep 03, 2026, 06:12 PM UTC
M
CLYM116 shows deep, durable APRIL suppression; 12-week dosing supported
CLYM116, an anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression and favorable safety in phase I, with reductions in IgA, Gd-IgA1 and IgM. PK/PD supports 12-week dosing; phase II and III pla
EQUITY | Sep 03, 2026, 01:41 PM UTC
M
Climb Bio reports Phase 1 CLYM116 data with durable suppression
Climb Bio announced Phase 1 data for CLYM116 showing a ~29-day half-life and rapid, durable APRIL and IgA suppression with favorable tolerability.
REGULATION | Sep 03, 2026, 11:53 AM UTC
M
CLYM116 Phase 1 data backs every-12-week dosing plan
Initial Phase 1 results for CLYM116 in healthy volunteers reported robust biomarker suppression, favorable safety, and a long half-life supporting every-12-week dosing; Phase 2 NAVIGATE-2 will confirm ahead of Phase 3.
EQUITY | Sep 03, 2026, 11:48 AM UTC
M
Climb Bio’s CLYM116 Phase 1 supports every-12-week dosing in IgA nephropathy
Phase 1 for CLYM116 showed prolonged half-life, strong APRIL and IgA suppression, and a favorable safety profile, supporting Q12W dosing in IgA nephropathy. Phase 2/3 planned; key data expected in 2027.
EQUITY | Sep 03, 2026, 11:10 AM UTC
M
Climb Bio says CLYM116 Phase 1 data show ~29-day half-life in IgA nephropathy
Single 320 mg CLYM116 dose drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks, with ~29-day half-life. Treatment was generally well-tolerated with no serious AEs, dose-limiting toxi
EQUITY | Sep 03, 2026, 11:08 AM UTC
M
Climb Bio announces CLYM116 Phase 1 data in IgA nephropathy
Climb Bio says CLYM116 Phase 1 data shows prolonged half-life and APRIL suppression supporting every-12-week dosing in IgA nephropathy.
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
Climb Bio to participate in upcoming investor conferences
Climb Bio said members of its executive team will participate in upcoming investor conferences, per the company’s announcement.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
CLYM - Climb Bio to Present at Upcoming Investor Conferences
CLYM - Climb Bio to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
CLYM - Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
CLYM - Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 06, 2026, 11:01 AM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
RBC Initiates CLYM Outperform
RBC starts CLYM with Outperform rating
EQUITY | Aug 03, 2026, 11:48 AM UTC
M
Analysts Initiate Coverage
Multiple stocks receive new analyst coverage
EQUITY | Aug 03, 2026, 10:58 AM UTC